Trial Profile
A open-label stratified phase II study in patients with hormone receptor positive breast cancer with bortezomib (Velcade) in the reversal of endocrine resistance
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2011
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Aromatase inhibitors; Selective estrogen receptor modulators
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms HOBO
- 24 Mar 2011 New trial record